These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 20452889

  • 1. Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
    Ortu F, Weimer LE, Floridia M, Manconi PE.
    Eur J Med Res; 2010 Feb 26; 15(2):81-3. PubMed ID: 20452889
    [Abstract] [Full Text] [Related]

  • 2. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
    Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P, STARTMRK Investigators.
    J Acquir Immune Defic Syndr; 2013 May 01; 63(1):77-85. PubMed ID: 23412015
    [Abstract] [Full Text] [Related]

  • 3. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
    Naggie S, Sulkowski MS.
    Gastroenterology; 2012 May 01; 142(6):1324-1334.e3. PubMed ID: 22537439
    [Abstract] [Full Text] [Related]

  • 4. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.
    HIV Clin Trials; 2011 May 01; 12(5):255-67. PubMed ID: 22180523
    [Abstract] [Full Text] [Related]

  • 5. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr 01; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 6. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
    Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, Girard PM, Henry K, Nguyen T, Piontkowsky D, Garner W, White K, Guyer B.
    Lancet Infect Dis; 2014 Jul 01; 14(7):590-9. PubMed ID: 24908550
    [Abstract] [Full Text] [Related]

  • 7. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D.
    Lancet Infect Dis; 2014 Jul 01; 14(7):581-9. PubMed ID: 24908551
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
    Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Ríos-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA.
    J Antimicrob Chemother; 2008 Dec 01; 62(6):1365-73. PubMed ID: 18854330
    [Abstract] [Full Text] [Related]

  • 9. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
    Lewis MG, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, Yalley-Ogunro J, Greenhouse J, Titti F, Garaci E, Savarino A.
    Retrovirology; 2010 Mar 16; 7():21. PubMed ID: 20233398
    [Abstract] [Full Text] [Related]

  • 10. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
    Mayer KH, Mimiaga MJ, Gelman M, Grasso C.
    J Acquir Immune Defic Syndr; 2012 Apr 01; 59(4):354-9. PubMed ID: 22267017
    [Abstract] [Full Text] [Related]

  • 11. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
    Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J, Walmsley S.
    AIDS; 2015 Jan 14; 29(2):167-74. PubMed ID: 25387312
    [Abstract] [Full Text] [Related]

  • 12. Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
    Wohl DA, Dumond JB, Blevins S, Pittard D, Ragan D, Wang R, Massengale K, Walsh K, Floris-Moore M, Eron JJ, Richardson A, Hudgens MG, Kashuba AD.
    Antimicrob Agents Chemother; 2013 Feb 14; 57(2):784-8. PubMed ID: 23183440
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
    Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P, STARTMRK investigators.
    Lancet; 2009 Sep 05; 374(9692):796-806. PubMed ID: 19647866
    [Abstract] [Full Text] [Related]

  • 14. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, Brinson C, Kulkarni R, Garner W, Ebrahimi R, Cao H, Cheng A, Szwarcberg J.
    HIV Clin Trials; 2014 Sep 05; 15(2):51-6. PubMed ID: 24710918
    [Abstract] [Full Text] [Related]

  • 15. HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?
    Francisci D, Martinelli L, Weimer LE, Zazzi M, Floridia M, Masini G, Baldelli F.
    Clin Drug Investig; 2011 Sep 05; 31(5):345-9. PubMed ID: 21344955
    [Abstract] [Full Text] [Related]

  • 16. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
    Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, Clagett B, Pilch-Cooper HA, Rodriguez B, Feinberg J, Daar E, Mellors J, Kuritzkes D, Jacobson JM, Lederman MM.
    PLoS One; 2013 Sep 05; 8(12):e83514. PubMed ID: 24367599
    [Abstract] [Full Text] [Related]

  • 17. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A.
    Antivir Ther; 2010 Sep 05; 15(2):213-8. PubMed ID: 20386076
    [Abstract] [Full Text] [Related]

  • 18. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
    Kulkarni R, Hluhanich R, McColl DM, Miller MD, White KL.
    Antimicrob Agents Chemother; 2014 Oct 05; 58(10):6145-50. PubMed ID: 25092710
    [Abstract] [Full Text] [Related]

  • 19. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A, Weimer LE, Manfredi R, Fragola V, Ferrari C.
    West Indian Med J; 2012 Dec 05; 61(9):932-6. PubMed ID: 24020238
    [Abstract] [Full Text] [Related]

  • 20. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team.
    N Engl J Med; 2009 Dec 03; 361(23):2230-40. PubMed ID: 19952143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.